Herbalife Nutrition Ltd vs Oruka Therapeutics Inc. Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.76 (market cap $1.49B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 3.5× Herbalife Nutrition Ltd's market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (490,798 versus 1,708,975). Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HLF | ORKA | |
|---|---|---|
Market Cap | $1.49B | $5.18B |
Volume | 1,708,975 | 490,798 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $113.08 |
52-Week Low | $7.75 | $26.19 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.32B | $4.31B |
Signals from Pluang's Aura AI — not financial advice
HLF trades at $14.19, up 4.26% today, with a bullish technical signal and strong analyst consensus. The stock shows attractive valuation with a P/E of 9.11 and P/S of 0.29, supported by a gross profit margin of 77.7%. Recent news includes a $250 million share repurchase program and a planned CEO transition in October 2026. Cash flow trends indicate improving operational cash generation, with 2026 projected net cash flow turning positive at $50 million.
The outlook for HLF is positive, with a consensus price target of $19.00 implying 34% upside. Risks include negative shareholder equity, high debt levels, and mixed quarterly earnings performance. Revenue stability and margin expansion efforts provide a foundation for growth, but investor caution is warranted due to ongoing leadership changes and competitive pressures in the wellness sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →